Curtis J. Perry
ORCID: 0000-0003-3715-5332Also affiliated with Yale University
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 7 papers. Top paper: “A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1”.
Dijana Djureinovic, Shlomit Jessel, Irina Krykbaeva, Lin Zhang, Lucia Jilaveanu +17 more
Bao Wang, Jessica Wei, Antonio H. de O. Fonseca, Curtis J. Perry, Alexander Frey +6 more
Katie Liu, Ryan Liu, Gautham Ramshankar, Curtis J. Perry, Rachel J. Perry +1 more
Katie Liu, Ryan Liu, Gautham Ramshankar, Curtis J. Perry, Rachel J. Perry +1 more
Kathryn Clulo, Yuewei Fei, Therese Cordero Dumit, Frankie Scallo, Jerry William Allen +12 more
Alexander Frey, Yuewei Fei, Philippos Apolinário Costa, Jason Z Wang, Sina Ghadermarzi +11 more
Dijana Djureinovic, Shlomit Jessel, Irina Krykbaeva, Lin Zhang, Lucia B. Jilaveanu +17 more